Stay updated on INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial

Sign up to get notified when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Phase 3 clinical trial comparing the efficacy of ripretinib to sunitinib in patients with advanced Gastrointestinal Stromal Tumor (GIST) after treatment with Imatinib.
    Difference
    0.1%
    Check dated 2024-06-06T14:44:16.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants, specifying that patients must be 18 years or older with a histologic diagnosis of GIST and other specific health conditions. Previously, no information was provided about the participation criteria for collaborators and investigators.
    Difference
    27%
    Check dated 2024-05-22T21:30:32.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:44:56.000Z thumbnail image

Stay in the know with updates to INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.